S C R E E N I N G O F M U LT I D R U G - R E S I S T A N T O R G A N I S M S

chromID™ MRSA
Chromogenic medium for the rapid & reliable Screening
of Methicillin-Resistant S.aureus (MRSA)

Isolate MRSA Colonies

& Start Patient Isolation

from diagnosis,
the seeds of better health
Isolate MRSA Colonies
& Start Patient Isolation
chromID™ MRSA has been designed for the direct and definitive
identification of Methicillin-resistant Staphylococcus aureus.
It helps healthcare units actively reinforce MRSA surveillance
culture and control healthcare-associated infections.

Original Principle
Direct identification of MRSA strains is based
on the spontaneous green colouration
of α−glucosidase-producing colonies (patent)
and the presence of an antibiotic, cefoxitin.

Greater Rapidity
Immediate identification of S.aureus = Green colonies
after 18-24 hour incubation; no additional
reagents are required*

Greater Simplicity
• Extremely easy-to-read
• Ready-to-use medium
• Specific chromogenic media for MRSA
• Culture + isolation + identification
on the same medium

Stronger green colouration of colonies when plates read upside

down through the plate bottom.
 Greater Reliability
• Excellent performance for the screening of MRSA in terms of nutrient capacity,
detection sensitivity and colouration specificity
• Detection of MRSA strains, including hetero-resistant strains,
with the presence of cefoxitin
• Selective inhibition of most bacteria not belonging to the genus
Staphylococcus, as well as yeasts.

Screening specimens
(nose, throat, perineum, groin, axilla, skin)

chromID™ MRSA
Direct Screening Enrichment step
Incubation 18 - 24 h. Incubation 18 - 24 h.
ours
24 h
18-
n
atio

Green colonies =
ub
nc

MRSA identification
•I

0 chromID MRSA
30 Incubation 18 - 24 h.
C 43
TC If negative results,
eu sA
S. aur re-incubate for an additional
period of 24 hrs* Green colonies =
MRSA identification
If negative results,
re-incubate for an additional
period of 24 hrs*

usanne on
. e Hospital, Belgiu n. ides Pathology, B
n. V , La cti Erasm m me Nicola risb
HU a
Blan ctio

,ff
lliva eci

&
. No lle

MR provided b ab sp
MR from Mrs C en co
MR from Dr D. colle

ne
c, C

o
nh

, Au
m a nasal sw
y Su
sitive specim
sal specimen

strali
a
SA fro
SA po
S A na

ge
ge

ge

Ima
Ima

Ima

* See technical sheet for futher information

 chromID™ Range
Pre-plated Chromogenic Media for the Screening of Multidrug-Resistant Organisms
chromID MRSA .....................................................................................................Ref 43451 – 20 plates / Ref 43459 – 100 plates
New name of MRSA ID (same reference)

chromID ESBL ..............................................................................................................................................................................Ref 43481 - 20 plates

new chromID VRE.....................................................................................................................................................................................Ref 43002 - 20 plates
01-07 / 002GB99115A / This document is not legally binding. bioMérieux reserves the right to modify specifications without notice / BIOMÉRIEUX the blue logo, chromID and CPS and “from diagnosis the seeds of better health” are used, pending
and/or registred trademarks belonging to bioMérieux S.A. or one of its subsidiaries / bioMérieux SA RCS Lyon 673 620 399 / Photos : C. Ganet, N. Bouchut, Getty Images / Printed in France / TL McCANN SANTÉ Lyon / RCS Lyon B 398 160 242

Other Chromogenic Media (same references)

chromID S.aureus ..................................................................................................................................................................Ref 43371 – 20 plates
New name of S.aureus ID

chromID Candida..............................................................................................................Ref 43631 - 20 plates / 43639 - 100 plates

New name of Candida ID2

chromID CPS®..........................................................................................................................Ref 43541 - 20 plates / 43549 - 100 plates

New name of CPS ID 3

chromID CPS / Columbia CNA + 5% sheep blood ................................................Ref 43463 - 10 plates

New name of CPS ID 3 / Columbia CNA + 5% sheep blood

chromID Strepto B ................................................................................................................................................................Ref 43461 - 20 plates

New name of Strepto B ID

chromID Salmonella.....................................................................................................Ref 43621 - 20 plates / 43629 - 100 plates

New name of SM ID2

chromID O157H7 .............................................................................................................................................Ref 42605 - 6 x 200 ml bottles

New name of O157:H7 ID

GUIDELINES: PUBLICATIONS:
Muto C.A., J.A. Jernigan, B.E.Ostrowsky, H.M. Richet, W.R. Jarvis, Development and evaluation of a chromogenic agar medium
J.M., Boyce, B.R. Farr. for methicillin-resistant Staphylococcus aureus.
2003. SHEA Guideline for preventing nosocomial transmission of PERRY J.D., DAVIES A., BUTTERWORTH L.A. and al . Journal of
multidrug-resistant strains of Staphylococcus aureus and Clinical Microbiology, Oct 2004, vol. 42, n° 10, p. 4519-4523
Enterococcus. Infect. Control. Hosp. Epidemiol 24:362-386.
Evaluation of three chromogenic media and ORSAB for
Siegel Jane D., MD; Rhinehart Emily, RN MPH CIC; Jackson surveillance cultures of methicillin-resistant Staphylococcus aureus.
Marguerite, PhD; Chiarello Linda, RN MS I. Nahimana, P. Francioli, D. S. Blanc. Journal Clin Microb and Infect
The Healthcare Infection Control Practices Advisory Committee.
Performance of MRSA ID, a New Chromogenic Medium for
Management of Multidrug-Resistant Organism In Healthcare
Detection of Methicillin-Resistant Staphylococcus aureus.
Setting, 2006. Centers for Disease Control and Prevention.
Bram M. W. Diederen, Marie-Louise van Leest, Inge van Duijn, Piet
Willemse, Peter H. J. van Keulen, and Jan A. J. W. Kluytmans. Journal
Coia J.E., Duckworth G.J., Edwards D.I., Farrigton M., Fry C.,
of clinical Microbiology, Feb. 2006, p. 586–588 Vol. 44, No. 2
Humphrey H., Mallaghan C., Tucker D.R., for the Joint Working
Party of the British Society of Antimicrobial Chemiotherapy, the
Hospital Infection Society and the Infection Nurses Association.
Guidelines for the control and prevention of methicillin-resistant
Staphylococcus aureus (MRSA) in Healthcare facilities. Journal of
Hospital Infection (2006) 635, S1-S44.

bioMérieux S.A.
69280 Marcy l’Etoile
France
Tel. : 33 (0)4 78 87 20 00
Fax : 33 (0)4 78 87 20 90 chromID MRSA is a marked product

www.biomerieux.com